摘要
目的探讨利拉鲁肽联合阿卡波糖片治疗肥胖2型糖尿病患者的临床疗效。方法选取肥胖2型糖尿病患者80例作为研究对象,采用随机数字表法分为A组和B组,每组40例,A组患者给予利拉鲁肽联合阿卡波糖片联合治疗,B组单用阿卡波糖片治疗,两组患者均控制饮食,规律运动,观察比较两组患者治疗前后血糖、糖化血红蛋白(Hb A1c)、空腹胰岛素(FINS)、血脂、体重指数(BMI)、胰岛素抵抗指数(HOMA-IR)变化情况。结果治疗后两组患者空腹血糖(FPG)、餐后血糖(2h PG)、糖化血红蛋白(Hb A1c)、胆固醇(Tc)、三酰甘油(TG)水平均明显降低,且A组低于B组,差异有统计学意义(P<0.05);治疗后A组患者体重指数(BMI)、胰岛素抵抗指数(HOMA-IR)水平显著下降且低于B组(P<0.05),B组患者BMI、HOMA-IR水平治疗前后比较差异无统计学意义(P>0.05)。结论与单用阿卡波糖片比较,联合应用利拉鲁肽和阿卡波糖片治疗肥胖2型糖尿糖尿病患者可以更好地控制血糖,减轻体重,改善血脂代谢,减轻胰岛素抵抗,且不增加低血糖等不良反应的发生率。
Objective To explore the clinical curative effect of liraglutide combined with acarbose in the treatment of patients with obesity type 2 diabetes. Methods A total of 80 patients with obesity type 2 diabetes were randomly divided into group A and group B, with 40 cases in each group, the group A was treated with liraglutide combined with acarbose, while the group B received acarbose alone, the two groups were given regular diet and exercise guidance, the blood glucose, glyeosylated hemoglobin （HbAlc）, fasting insulin （FINS）, blood lipid, body mass index （BMI） and insulin resistance index （HOMA-IR） were observed before and after treatment, and the above indexes were compared between the two groups. Results The levels of fasting blood glucose （ FPG）, postprandial blood glucose （ 2hPG）, glycosylated hemoglobin （ HbA1 c ）, cholesterol （ Tc ）, triglyceride （TG） decreased significantly in the two groups after treatment in contrast with those before treatment, and the decreased in the group A was more significant （P 〈 0. 05） ; after treatment, the body mass index （ BMI） and insulin resistance index （HOMA-IR） in the group A was significantly lower than those in the group B （P 〈 0.05 ） , there was no significant difference of body mass index （BMI） and insulin resistance index （HOMA-IR） in the group B before and after treatment （P 〉 0.05 ）. Conclusions Compare with acarbose, liraglutide combined with acarbose in the treatment of patients with obesity type 2 diabetes can control blood sugar, lose body weight, improve blood lipid metabolism, reduce insulin resistance more effective, and will not increase the incidence rate of hypoglycemia.
出处
《内科》
2017年第3期319-322,共4页
Internal Medicine
关键词
2型糖尿病
肥胖
治疗
利拉鲁肽
阿卡波糖
胰岛素抵抗
体重指数
血糖
血脂
Type 2 diabetes mellitus
Obesity
Treatment
Liraglutide
Acarbose
Insulin resistance
Body mass index
Blood glucose
Blood lipid
